Chinook Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for kidney diseases. Co.'s lead program is atrasentan, an endothelin A receptor antagonist that was in-licensed from AbbVie, through its affiliate AbbVie Ireland Unlimited Company. Co.'s second product candidate, BION-1301, is an anti-APRIL monoclonal antibody also in development for patients with Immunoglobulin A Nephropathy. Co. is also developing its third program, CHK-336 for the treatment of primary hyperoxaluria. In addition, Co. is conducting research programs in several other rare, severe chronic kidney diseases. The KDNY stock yearly return is shown above.
The yearly return on the KDNY stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the KDNY annual return calculation with any dividends reinvested as applicable (on ex-dates).
|